P. Ioan, E. Carosati, M. Micucci, G. Cruciani, F. Broccatelli, B. S. Zhorov, A. Chiarini and R. Budriesi Pages 4901 - 4922 ( 22 )
Since the pioneering studies of Fleckenstein and co-workers, L-Type Calcium Channel (LTCC) blockers have attracted large interest due to their effectiveness in treating several cardiovascular diseases. Medicinal chemists achieved high potency and tissue selectivity by decorating the 1-4-DHP nucleus, the most studied scaffold among LTCC blockers. Nowadays it is clear that the 1,4-DHP nucleus is a privileged scaffold since, when appropriately substituted, it can selectively modulate diverse receptors, channels and enzymes. Therefore, the 1,4-DHP scaffold could be used to treat various diseases by a single-ligand multi-target approach. In this review, we describe the structure-activity relationships of 1,4-DHPs at ion channels, G-protein coupled receptors, and outline the potential for future therapeutic applications.
1,4-Dihydropyridines,4-DHPs,1,4-Dihydropyridine scaffold,Ion Channels,G-protein coupled receptors,modulators,therapeutic applications,multi-target ligand,Voltage-Gated Calcium Channels,Ligand-Gated Ion Channels,Calcium antagonists,L-Type Calcium Channel blockers
, , , , , , , Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Bologna, Via Belmeloro 6, 40126 Bologna, Italia.